Across TCGA pan-cancer cohorts, IGLV2-14 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IGLV2-14 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher IGLV2-14 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGLV2-14 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LSCC, PDAC, and CCRCC are the cancer types where IGLV2-14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.881	0.990	.006	11	view →
PDAC	DFS	Median	IV	0.299	0.934	.038	6	view →
CCRCC	DFS	Tertile	All	0.833	0.608	.019	5	view →
LUAD	OS	Quartile	II,III,IV	0.386	0.812	.029	2	view →
UCEC	OS	Quartile	All	0.802	0.967	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: IGLV2-14 tumor-vs-normal RNA expression · all IGLV2-14 data types